<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90E10C07-7B4F-45DD-AA82-4D008528D8DD"><gtr:id>90E10C07-7B4F-45DD-AA82-4D008528D8DD</gtr:id><gtr:name>Constellation Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90E10C07-7B4F-45DD-AA82-4D008528D8DD"><gtr:id>90E10C07-7B4F-45DD-AA82-4D008528D8DD</gtr:id><gtr:name>Constellation Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/24B22393-0813-4A95-8DFA-3AB068F9438D"><gtr:id>24B22393-0813-4A95-8DFA-3AB068F9438D</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Gamblin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117584222"><gtr:id>7D83C995-B98B-4757-9550-040F6A64DCAA</gtr:id><gtr:title>Structural &amp;amp; functional studies of protein molecules involved in cancer and infectious or metabolic diseases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117584222</gtr:grantReference><gtr:abstractText>Our principle interest is to understand the basic science underlying the mode of action of protein molecules important in disease states. Current activities fall into three main areas. Two of these, the regulation of chromatin structure and transcription, and the mechanisms involved in signal transduction pathways, impact on our understanding of the causes of cancer. Our third area of interest concerns understanding the mode of action of proteins that are directly implicated in infectious or metabolic diseases. Our principle aim is to use protein crystallography, biochemical and biophysical techniques, together with cell biological approaches carried out with suitable collaborators, to gain insights into how these systems function at the molecular level. An additional objective of all our work is to be vigilant for any findings that may enable the development of therapeutic approaches towards any of these disease states. In such cases, we seek to use our understanding of the relevant systems to facilitate the translation of our ideas or reagents to suitable partners for development and exploitation.</gtr:abstractText><gtr:technicalSummary>The aim of our research is to use structural biology to probe the mechanisms of protein molecules fundamental to cellular and disease processes. Our main approach involves structure determination by x-ray crystallography integrated with biochemical, biophysical and cell-biological experiments to facilitate and interpret our structural data. We work on protein/protein or protein/ligand interactions that either involve fundamental cellular regulatory systems like signalling via small GTPases or chromatin regulation by methylation or proteins important in major disease areas such as the surface glycoproteins of influenza virus or the major kinases complexes implicated in the development of type II diabetes. Wherever appropriate we seek to exploit our findings for pharmacological benefit through patenting and partnership with MRCT. We are working on the structural basis of signalling of the small GTPase Arf through its interaction and regulation of BAR domain protein arfaptin. We use x-ray crystallography as well as negative stain and cryo electron microscopy to understand the molecular basis of membrane remodelling by this system. In collaboration with our Division of Molecular Neuroendocrinology we are determining the physiological role of this system in controlling vesicle transport across the Golgi. Our interest in chromatin regulation through post-translational modifications has led us into working on polycomb repressive complex (PRC) which is a histone methyltransferase strongly implicated in the development of prostate cancer. We are using protein chemistry, molecular biology and x-ray crystallography to address the molecular mechanism of this large protein complex. Our principle collaborator is with Prof Danny Reinberg. As part of our longstanding collaboration with the Division of Virology we are working on the structural and functional characterisation of the two principle surface glycoproteins of influenza; neuraminidase (NA) and hemagglutinin (HA). With NA we are working with MRCT to develop novel inhibitors of this enzyme to expand the current range of anti-virals effective against influenza (Tamiflu &amp;amp; Relenza). We are using x-ray crystallography to understand the basis of drug binding/specificity and the basis of resistance mutations. On HA we are using x-ray crystallography and biochemical and biophysical approaches to understand the basis of the specificity of host cell interactions. This work is closely informed by the work of the World Influenza Centre housed at Mill Hill and is an important contribution to the surveillance effort. In collaboration with Prof Dave Carling we are investigating the mechanisms of the diabetes-associated kinases AMPK and LKB1. We are using protein chemistry, molecular biology and x-ray crystallography to determine the structure/function relationship in these enzymes with the ultimate aim of informing the development of novel drugs for targeting diabetes.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>11920319</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Studies on AMPK with AstraZeneca</gtr:description><gtr:id>A1420B40-B690-4767-AB5A-3295135ACA6B</gtr:id><gtr:impact>Facilitated by the development of AstraZeneca program</gtr:impact><gtr:outcomeId>KJjDWPQYz84-1</gtr:outcomeId><gtr:partnerContribution>Insight into protein behaviour</gtr:partnerContribution><gtr:piContribution>We have supplied expertise, materials and advice to GSK, as well as a licence to a patent for their type 2 diabetes drug program.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Constellation Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Epigenetic targets for cancer therapy</gtr:description><gtr:id>8A203384-E4A1-4D8E-9CA5-42E18831E644</gtr:id><gtr:impact>Helped inform direction of Constellation's research strategy</gtr:impact><gtr:outcomeId>6F2B44FA533-1</gtr:outcomeId><gtr:partnerContribution>Insights into protein behaviour</gtr:partnerContribution><gtr:piContribution>We have supplied expertise, materials and licence to patent.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Studies on AMPK with GSK</gtr:description><gtr:id>93BACD01-4FA7-4C32-8019-1C2DA7C9D8F7</gtr:id><gtr:impact>Facilitated the development of GSK program</gtr:impact><gtr:outcomeId>D1C54CEB45D-1</gtr:outcomeId><gtr:partnerContribution>Insights into protein behaviour</gtr:partnerContribution><gtr:piContribution>We have supplied expertise, materials and advice to GSK, as well as a licence to a patent for their type 2 diabetes drug program.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D52595C5-BD0F-46A8-A2D0-B842ED2572E9</gtr:id><gtr:impact>The students visited the NIMR to hear short research talks and participate in a number of workshops including practical crystallography, chemistry and using microscopes to view chick embryos, flies etc.

Generated interest in the molecular aspects of biological science research.</gtr:impact><gtr:outcomeId>mUBYfDj69Sd</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.nimr.mrc.ac.uk/schools/schools-day/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>163760</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome-Research Grant-2009</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1DCBBB58-5370-4399-AFC7-D569AC4CDB1B</gtr:id><gtr:outcomeId>53FF20A1EA90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>293600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Influenza Grant (2006)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0EB9F551-312A-47BC-96FD-6B5FD7CF4B3A</gtr:id><gtr:outcomeId>8E767857F920</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GlaxoSmithKline</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>6118B6B3-84B5-407C-A889-117638A4254E</gtr:id><gtr:outcomeId>ktSRowSrdG40</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Crystal structure of EED bound to an analogue of tri-methyl lysine.</gtr:description><gtr:grantRef>MC_U117584222</gtr:grantRef><gtr:id>4C45D5E9-E62A-4252-8916-A49E0AF3A065</gtr:id><gtr:impact>Patent applied for Dec 2008. Licensed to company.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>6581ED521D5</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Crystal structure of EED</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Structure of Group-1 influenza neuraminidases reveals unexpected difference close to the active site that has potential for novel drug development.</gtr:description><gtr:grantRef>MC_U117584222</gtr:grantRef><gtr:id>DC42C376-344A-4EE8-9A03-D2C63147635E</gtr:id><gtr:impact>IP licensed to University of St Andrews, Nov 2007. Patent granted in China.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>6995BB1F1B5</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>N1 Crystal Structure</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Insights into nucleotide regulation of cellular energy balance from functional and structural studies.</gtr:description><gtr:grantRef>MC_U117584222</gtr:grantRef><gtr:id>2CDCA137-3BC6-4E50-8EE2-410FAC2C10AB</gtr:id><gtr:impact>UK patent applied for Aug 2007, access to patented information supplied on licence to GSK</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>514ABD7CDBE</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>AMP Kinase Crystal Structure</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence of drug resistant influenza on public health policy</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>2F64DF13-CA0B-4AC0-AAD2-8381DD556C78</gtr:id><gtr:outcomeId>EDB7220B2FA</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Protein</gtr:description><gtr:id>877BFBF1-93A3-4D55-B6EB-BF0B8FC75E60</gtr:id><gtr:impact>Material transferred to company July 2009</gtr:impact><gtr:outcomeId>2DB0CEEAC6C</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AMP kinase crystal structure</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4C4BE157-4562-4F6A-AEC5-A809FA0EE68C</gtr:id><gtr:title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fef4e6185e9282a90000b15259fa70f"><gtr:id>5fef4e6185e9282a90000b15259fa70f</gtr:id><gtr:otherNames>Corti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>hYevgABJp7o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B766C76-9532-4E20-9925-AA326B08F1C9</gtr:id><gtr:title>Structure of mammalian AMPK and its regulation by ADP.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea167df39b3dea34dd3da5e073e849d"><gtr:id>6ea167df39b3dea34dd3da5e073e849d</gtr:id><gtr:otherNames>Xiao B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>B5URrEWzuh6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B786AD6-3F3F-4DFD-9522-102E64B0C27E</gtr:id><gtr:title>Specificity and mechanism of the histone methyltransferase Pr-Set7.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea167df39b3dea34dd3da5e073e849d"><gtr:id>6ea167df39b3dea34dd3da5e073e849d</gtr:id><gtr:otherNames>Xiao B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn><gtr:outcomeId>7FE10EB9121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A40A45D-03A1-4081-8200-C047F3569DE4</gtr:id><gtr:title>Enhanced human receptor binding by H5 haemagglutinins.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5b7df65b73711afafabedbac73ca4cb"><gtr:id>c5b7df65b73711afafabedbac73ca4cb</gtr:id><gtr:otherNames>Xiong X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5460aba8159f13.02705442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3992E007-1F5A-4F69-B146-D86595AADCAC</gtr:id><gtr:title>Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eebe7ac7302c4af50784d3def7b59d2"><gtr:id>3eebe7ac7302c4af50784d3def7b59d2</gtr:id><gtr:otherNames>Sanulli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>5643221d0a42a8.28792670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7164203E-0C2F-48AE-8065-BD4750A5F95F</gtr:id><gtr:title>Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5360052184835a92de21a35704db22ac"><gtr:id>5360052184835a92de21a35704db22ac</gtr:id><gtr:otherNames>Lin YP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_14654_1218841110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E829521-5704-4D74-9F9A-9C2174803778</gtr:id><gtr:title>Changes in the hemagglutinin of H5N1 viruses during human infection--influence on receptor binding.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8a186f45719f9b90df8ad838fda1fd1"><gtr:id>f8a186f45719f9b90df8ad838fda1fd1</gtr:id><gtr:otherNames>Crusat M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>doi_14654_013_08_010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A98B7648-4F6F-4F13-B4EA-9915C95E9DEB</gtr:id><gtr:title>Structural basis for AMP binding to mammalian AMP-activated protein kinase.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea167df39b3dea34dd3da5e073e849d"><gtr:id>6ea167df39b3dea34dd3da5e073e849d</gtr:id><gtr:otherNames>Xiao B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>62904523775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA45E512-D796-4A4A-A63A-7A2455EA1131</gtr:id><gtr:title>Reading, writing and editing methylated lysines on histone tails: new insights from recent structural studies.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fde9469de7cdd380416294d5c3501bf4"><gtr:id>fde9469de7cdd380416294d5c3501bf4</gtr:id><gtr:otherNames>Justin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>WU2hCUMs4Te</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DFEE0FA-3DA2-40F5-8196-82997AF41610</gtr:id><gtr:title>AMP-activated protein kinase: nature's energy sensor.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e855d7dab8da0efe17a581fbe1691b1"><gtr:id>8e855d7dab8da0efe17a581fbe1691b1</gtr:id><gtr:otherNames>Carling D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>jg2HYCgoup2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B1FFEF4-79AD-430E-92DA-D1EF95AACC05</gtr:id><gtr:title>Receptor binding by an H7N9 influenza virus from humans.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5b7df65b73711afafabedbac73ca4cb"><gtr:id>c5b7df65b73711afafabedbac73ca4cb</gtr:id><gtr:otherNames>Xiong X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_14654_ature12372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAE4D1B7-F066-4DBE-A312-B7257AB95366</gtr:id><gtr:title>Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5326701fa861c5afae566266fd3de076"><gtr:id>5326701fa861c5afae566266fd3de076</gtr:id><gtr:otherNames>Collins PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>ADCAAF7DD47</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F0C3873-877C-491F-9438-CB1E68DE934B</gtr:id><gtr:title>ADP regulates SNF1, the Saccharomyces cerevisiae homolog of AMP-activated protein kinase.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee1f7275a928fd30b1942b9f1cd2f431"><gtr:id>ee1f7275a928fd30b1942b9f1cd2f431</gtr:id><gtr:otherNames>Mayer FV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>YUqki2b4VuP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>385F7919-7516-4B86-BD7B-C535EEA25540</gtr:id><gtr:title>Evolving Catalytic Properties of the MLL Family SET Domain.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>5643221d3597c3.53334040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74696BFD-0ADD-4A42-AD15-03ACB1DA387A</gtr:id><gtr:title>Antibiotic recognition by binuclear metallo-beta-lactamases revealed by X-ray crystallography.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79c6810bc24c5416cc1731b11428ae57"><gtr:id>79c6810bc24c5416cc1731b11428ae57</gtr:id><gtr:otherNames>Spencer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>C2AC8A9B068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB31062A-FE0A-4294-9081-CA1977ACD4E8</gtr:id><gtr:title>Recent evolution of equine influenza and the origin of canine influenza.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5326701fa861c5afae566266fd3de076"><gtr:id>5326701fa861c5afae566266fd3de076</gtr:id><gtr:otherNames>Collins PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5460aba7e4e082.75512406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61DABB80-EB9F-45E5-AC07-1F28C727D4B1</gtr:id><gtr:title>Structural basis for oseltamivir resistance of influenza viruses.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5326701fa861c5afae566266fd3de076"><gtr:id>5326701fa861c5afae566266fd3de076</gtr:id><gtr:otherNames>Collins PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>63968141D9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1465245-0991-49E0-B107-2AF7063C46DB</gtr:id><gtr:title>Receptor binding by a ferret-transmissible H5 avian influenza virus.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5b7df65b73711afafabedbac73ca4cb"><gtr:id>c5b7df65b73711afafabedbac73ca4cb</gtr:id><gtr:otherNames>Xiong X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_14654_ature12144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D6ABC56-176F-41A6-97A9-798A95765239</gtr:id><gtr:title>A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18113a2d750140919bbc345f2f67feb"><gtr:id>f18113a2d750140919bbc345f2f67feb</gtr:id><gtr:otherNames>Hu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14654_24_22238297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2CBF9A7-EAE8-4844-B8A3-E79A345EFA41</gtr:id><gtr:title>Role of the polycomb protein EED in the propagation of repressive histone marks.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65c371bb72be6739a76d28794b47461f"><gtr:id>65c371bb72be6739a76d28794b47461f</gtr:id><gtr:otherNames>Margueron R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>63217511FEC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79C73EB4-0FF4-461F-A9CE-46BDE10D571F</gtr:id><gtr:title>Structural basis of AMPK regulation by small molecule activators.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea167df39b3dea34dd3da5e073e849d"><gtr:id>6ea167df39b3dea34dd3da5e073e849d</gtr:id><gtr:otherNames>Xiao B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5460aba85bb011.90505625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4089E7B9-73E8-49F0-A8B9-3ACC3A6B7298</gtr:id><gtr:title>H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89099cfb4d65bf4ec8d4f94e0c93261c"><gtr:id>89099cfb4d65bf4ec8d4f94e0c93261c</gtr:id><gtr:otherNames>van der Vries E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_14654_24_23028314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4694E860-5287-466D-9747-45AFE6CDF705</gtr:id><gtr:title>Structures of receptor complexes formed by hemagglutinins from the Asian Influenza pandemic of 1957.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242b3836ccf09f5018352f691c3cf3bd"><gtr:id>242b3836ccf09f5018352f691c3cf3bd</gtr:id><gtr:otherNames>Liu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>741B48A8ECD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E0DDA63-B744-49EE-ACA3-3E77B2CBDD22</gtr:id><gtr:title>Influenza hemagglutinin and neuraminidase membrane glycoproteins.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49ccfa07b6d44200f9e48823625230d"><gtr:id>a49ccfa07b6d44200f9e48823625230d</gtr:id><gtr:otherNames>Gamblin SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>Rd3YTbqmFMm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C8D946E-C183-4749-8190-7E2FEC1F14FD</gtr:id><gtr:title>Recognition of sulphated and fucosylated receptor sialosides by A/Vietnam/1194/2004 (H5N1) influenza virus.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5b7df65b73711afafabedbac73ca4cb"><gtr:id>c5b7df65b73711afafabedbac73ca4cb</gtr:id><gtr:otherNames>Xiong X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>doi_14654_013_08_007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28E0EF35-772C-4F06-9272-FA040343B697</gtr:id><gtr:title>AMP-activated protein kinase: also regulated by ADP?</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96d82511f788d934e6c24a4e2dcf24da"><gtr:id>96d82511f788d934e6c24a4e2dcf24da</gtr:id><gtr:otherNames>Hardie DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>ZcXceAoByMA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C03E16D9-7860-4D0F-81F2-A76023DEA218</gtr:id><gtr:title>The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3429df0f1fb4f1013e2e6f82c8183d45"><gtr:id>3429df0f1fb4f1013e2e6f82c8183d45</gtr:id><gtr:otherNames>Russell RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>69AE2C4F89C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117584222</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>